1. Introduction {#sec1}
===============

Spermatic cord lymphoma is a rare lethal disease. To our knowledge, searching both English and Japanese literature, only thirty-three cases including our case have been reported \[[@B2]--[@B9]\]. It has a poor prognosis even in stage I disease when treated locally, therefore, multidisciplinary treatment for early stage is recommended. Here we report a new case of spermatic cord lymphoma, which was found in stage IV disease. We also review literature and discuss treatment options.

2. Case Report {#sec2}
==============

In July 2010, a 62-year-old man visited an urologist with a complaint of a left intrascrotal mass and was placed under clinical observation without treatment. Two months later, a swelling of the right tonsil appeared, and he visited an otorhinolaryngologist. After a biopsy of the right tonsil, he was diagnosed with diffuse large B-cell lymphoma (DLBCL) and was admitted to our hospital. Physical examination showed that the right tonsil swelled up beyond the midline, right cervical and left supraclavian lymph nodes were palpable, and a 50-mm mass existed along the left spermatic cord. He also had night sweats. In the blood examination, high levels of serum soluble interleukin-2 receptor were detected (5290 U/mL). Ultrasonography showed a 50 mm tumorous lesion in maximum diameter in the left spermatic cord and a 5 mm mass in the right spermatic cord, respectively. Computed tomographic scan (CT) showed the swelling of the right tonsil and the enlargement of right cervical, left supraclavian, and para-aortic lymph nodes. 67 Ga scintigraphy showed intense uptake in the same lesions which were detected in CT, but no uptake in groins ([Figure 1](#fig1){ref-type="fig"}). Bone marrow aspiration showed a few large atypical cells that were positive for CD20 and negative for CD3, which suggests the invasion of lymphoma to the bone marrow. Based on these findings, he was clinically diagnosed as DLBCL at stage IVB (Ann Arbor Staging). In December 2010, he underwent left radical orchiectomy for confirming the diagnosis and mass reduction. Macroscopically, a white 67 mm tumor in maximum diameter existed around the left spermatic cord, but the testis and the epididymis were not involved ([Figure 2](#fig2){ref-type="fig"}). It consisted of proliferative large atypical lymphocytes ([Figure 3](#fig3){ref-type="fig"}). Immunohistochemistry revealed that the tumor cells were positive for CD20 and negative for CD3. Histopathological diagnosis was DLBCL of the left spermatic cord. As adjuvant therapy, he completed both 6 cycles of rituximab added to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and 4 cycles of intrathecal methotrexate (IT-MTX) for central nervous system (CNS) prophylaxis. Then, he also underwent radiotherapy (RT) to the right testis for prophylaxis of contralateral testicular relapse. CT performed 4 months after the orchiectomy showed that all lesions either disappeared or reduced, and that there was no new lesions.

3. Discussion {#sec3}
=============

Male gonadal involvement is relatively uncommon in malignant lymphoma. Of these lymphomas, testicular lymphoma is the most frequent, accounting about 1% of all nonHodgkin\'s lymphomas \[[@B1]\]. On the other hand, spermatic cord lymphoma is very rare, and to the best of our knowledge, only thirty-three cases including our own case have been reported ([Table 1](#tab1){ref-type="table"}) \[[@B2]--[@B9]\]. The patients ranged in age from 20 to 89 years (mean age, 60-year-old). Middle-aged men (14 out of 33 cases) and older men (15 out of 33 cases) were mainly affected \[[@B10]\]. Most cases were stage I disease at the time of diagnosis (stage I, 21 cases; stage II, 6 cases; stage III, 2 cases; stage IV, 4 cases), nevertheless, they apparently have a poor prognosis (median survival, 12.2 months). Our case was already in stage IV at presentation. In general, it is difficult to detect the primary site when a patient with malignant lymphoma has multiple lesions. However, the first manifestation of our case was the spermatic cord tumor. Spermatic cord lymphoma has a tendency to spread or relapse towards para-aortic lymph nodes, while lymphomas derived from different primary lesions hardly metastasize to a spermatic cord in an early stage \[[@B6]\]. Therefore, we assumed the primary site in our case might be the spermatic cord. Histologically reviewing, intermediate-grade lymphomas (Working Formulation), centroblast or centroblastic-centrocytic lymphomas (Kiel classification), and DLBCL (WHO classification) were most frequently observed, except two cases which suffered from Burkitt\'s subtype \[[@B2], [@B5]\]. All cases that the immunophenotypical study was performed showed a B-cell phenotype.

It is said that spermatic cord lymphoma is clinicopathologically similar to primary testicular lymphoma (PTL). PTL is a potentially fatal disease second only to primary brain lymphoma; median survival is between 12 and 24 months \[[@B1]\]. It is due to failures in contralateral testis, CNS, and extranodal sites. Recently, an international phase II trial showed that the recommended first-line treatment for stage I or II PTL is orchiectomy followed by R-CHOP, IT-MTX, and RT to the contralateral testis \[[@B10]\]. In the same way, it has been said that multidisciplinary treatments should be given in early staged spermatic cord lymphoma, but actually was not. Reviewing reported cases of stage I spermatic cord lymphoma, the initial treatment was only orchiectomy with or without RT by the 1980s, and the ratio of combining chemotherapy or not has become half and half since the 1990s. No case except ours underwent IT-MTX. Median survival of stage I spermatic cord lymphoma treated only orchiectomy with or without RT was 18.2 months, while 5-year overall survival rates of early staged PTL treated multidisciplinarily were 85% in the recent trial \[[@B10]\]. It suggests that combined treatment with R-CHOP, IT-MTX, and RT to the contralateral testis will attribute a better outcome in early staged spermatic cord lymphoma.

On the other hand, the treatment of choice for stage III or IV disease in spermatic cord lymphoma still remains to be determined. For advanced PTL, the recommended first-line treatment is R-CHOP, however a median survival of less than six months is reported \[[@B1]\]. Despite a higher rate of relapse in the contralateral testis (up to 50% of patients), RT to the contralateral testis is recommended by some authors, while others propose RT only for symptomatic patients or in the case of bulky disease. IT-MTX to prevent CNS relapse, which occurs in approximately 50% of patients, is also considered in patients achieving complete remission.

![Computed tomographic scan (CT) showing the swelling of the right tonsil and the enlargement of right cervical, left supraclavian, and para-aortic lymph nodes. 67 Ga scintigraphy showing intense uptake in the same lesions which were detected in CT.](CRIM2012-513707.001){#fig1}

![Gross appearance of the surgical specimen showing a white 67 mm tumor around the left spermatic cord.](CRIM2012-513707.002){#fig2}

![Microscopic features of the tumor consisting of proliferative large atypical lymphocytes.](CRIM2012-513707.003){#fig3}

###### 

Reported cases of spermatic cord lymphoma.

         Author              Age, *y*   Stage   Histology   Immuno-phenotype   Initial treatment   Survival, mo
  ------ ------------------- ---------- ------- ----------- ------------------ ------------------- --------------
  1934   Fresnais            73         IE      LS          NA                 O                   DOD, 5
  1936   Slotkin             36         IE      LS          NA                 O                   DOD, 1
  1949   Hector              64         IE      RES         NA                 O                   DOD, 62
  1954   Wetterwald          49         IIE     LB          NA                 O                   DOD, 1
  1957   Pelot               21         IE      RS          NA                 O, RT               DOD, 12
  1970   Bologna             42         IE      LRS         NA                 O, RT               DOD, 6
  1970   Gotou               57         IE      RS          NA                 O, RT               NA
  1972   Iwata               30         IIE     LS          NA                 O, CT               DOD, 3
  1972   Katou               75         III     RS          NA                 O, CT               DOD, 3
  1980   Karapandov          57         IE      CB/CC       NA                 O, RT               NA
  1982   Guena               46         IE      CB/CC       NA                 NA                  NA
  1982   Satou               49         IE      Burkitt     B                  O, CT               NA
  1986   Hautzer             54         IE      CBD         NA                 O                   DOD, 7
  1986   Hanada              74         IE      DLC         NA                 O                   DOD, 5
  1989   Zwanger-Mendelson   20         IV      Burkitt     B                  O                   DOD, 1
  1989   Ooyama              66         IIE     DLC         NA                 O, CT               NA
  1990   D\'Abrosca          89         IE      CBD         NA                 NA                  DOD, NA
  1990   Nishimura           47         IIE     DLC         NA                 O, CT               NA
  1994   Möller              48         IV      CBD         B                  NA                  DOD, 8
  1994   Kawanishi           66         IE      DMC         NA                 O, CT, RT           NA
  1994   Asanuma             78         IE      DLC         NA                 CT                  NA
  1994   Oonishi             76         IE      DMC         NA                 O                   NA
  1996   Lands               57         IE      DLC         B                  O                   DOD, 26
  1997   Umehara             78         IE      DLC         NA                 O                   NA
  1998   Ichiyanagi          77         IIE     DLC         B                  O, CT               DOD, 10
  2001   Okabe               76         IE      DMC         B                  O                   DOD, 40
  2007   Kawano              57         IIE     DLBCL       B                  O, CT               NA
  2008   Nakano              54         IVA     DLBCL       B                  O, CT               DOD, 5
  2009   Natsuizaka          75         IE      DLBCL       B                  O, CT               NA
  2009   Almeida             71         IE      DLBCL       B                  O, CT               NA
  2009   Suzuki              74         IIIA    DLBCL       B                  O, CT               DOD, 13
  2009   Asano               71         IE      DLBCL       B                  O, CT               NA
  2011   Our case            62         IVB     DLBCL       B                  O, CT, RT, IT       NA

O, orchiectomy; CT, chemotherapy; RT, radiotherapy; IT, intrathecal chemotherapy; CBD, centroblastic diffuse; CB/CC, centroblastic/centrocytic; LB, lymphoblastic; LS, lymphosarcoma; RS, reticulosarcoma; LRS, lymphoreticulosarcoma; RES, reticuloendotheliosarcoma; DLC, diffuse large cell; DMC, diffuse medium cell; DLBCL, diffuse large B-cell lymphoma; mo, months; NA, not available; DOD, died of disease.
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